• Strategies in Inter Partes Review Proceedings for Biotech/Pharma Patents
  • June 2, 2015 | Author: Robert H. Resis
  • Law Firm: Banner & Witcoff, Ltd. - Chicago Office
  • In October 2013, about one year after inter partes review (IPR) proceedings became available, the chief judge of the Federal Circuit called the Patent Trial and Appeal Board (PTAB) a “death squad.” Certainly, a high percentage of early IPR petitioners enjoyed success getting the PTAB to hold patent claims invalid, and the number of IPRs filed has steadily climbed.